Borough Park 1428 36th Street Suite 107 Brooklyn, NY 11218

Sheepshead Bay 2546 East 17th Street Fl, 1 Brooklyn, NY 11235

226 West 238th Street

Massapequa 97 Grand Avenue Bronx, NY 10463 Massapequa, NY 11758

Forest Hills 64-05 Yellowstone Blvd CF104 Forest Hills, NY 11375

FIDI Long Island City 30 Broad Street Suite 401 New York, NY 10004 36-36 33rd Suite 311 Long Island City, NY 11106

Gramercy 7 Gramercy Park West Lower Level New York, NY, 10003

E 70th St Upper East Side 225 E 70th Street E 56th & Park Midtown 120 East 56 Street Suite 300 New York, NY 10022 New York, NY 10021

> Central Park West 115 Central Park West Suite 15 New York, NY 10023

Suite 1E





Tarrytown 555 Taxter Road 3rd Floor

Port Jefferson 12 Medical Drive Suite B Port Jefferson Station, NY 11776

> Staten Island 27 New Dorp Lane Staten Island, NY 10306

Southampton 625 Hampton Road Southampton, NY 11968

Riverhead 1228 E Main Street Suite A Riverhead, NY 11901

Holbrook 233 Union Avenue Suite 207 Holbrook, NY 11741

Manhasset 333 East Shore Road Manhasset, NY 11030

Rockville Centre 165 North Village Avenue Suite 133 Rockville Center, NY 11570

> 1991 Marcus Ave Suite 110 Lake Success, NY, 11042

Woodbury 7600 Jericho Tpke, Lower Level, Suite C500 Woodbury NY 11797

OMVOH (mirikizumab-mrkz)

Provider Order Form	, D	Pate:
	TIENT INFORMATION	
		1
Name:	DOB:	SEX: M □ F □
ICD-10 code (required):	ICD-10 description:	
□NKDA Allergies:		Weight lbs/kg:
REFERRAL STATUS		
□New Referral □Referral Renewal □Medication/	Order Change □Benefits Verifica	tion Only Discontinuation Order
PHYSICIAN INFORMATION		
Referral Coordinator Name:	Referral Coordinator Emai	il:
Ordering Provider: Provider NPI:		
Referring Practice Name:	Phone:	Fax:
Practice Address:	City: St	tate: Zip Code:

INDICATIONS AND USAGE

OMVOHTM is an interleukin-23 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults (1)

DOSAGE AND ADMINISTRATION

Prior to Treatment Initiation

- Evaluate patients for tuberculosis (TB) infection. (2.1, 5.3)
- Obtain liver enzymes and bilirubin levels. (2.1, 5.4)
- Complete all age-appropriate vaccinations according to current Recommended Dosage
- The recommended induction dosage is 300 mg administered by intravenous infusion over at least 30 minutes at Weeks 0, 4, and 8.
- The recommended maintenance dosage is 200 mg administered by subcutaneous injection (given as two consecutive injections of 100 mg each) at Week 12, and every 4 weeks thereafter. (2.2)

Preparation and Administration

See the full prescribing information for preparation, administration and storage information for intravenous infusion and subcutaneous injection. (2.3, 2.4)

DOSAGE FORMS AND STRENGTH

Intravenous Infusion (3)

- Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial Subcutaneous Injection (3):
- Injection: 100 mg/mL solution in a single-dose prefilled pen

CONTRAINDICATIONS

History of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients. (4, 5.1).

WARNINGS AND PRECAUTIONS

- Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis and infusion-related reactions, have been reported. If a severe hypersensitivity reaction occurs, discontinue and initiate appropriate treatment. (5.1)
- Infections: OMVOH may increase the risk of infection. Do not initiate treatment with OMVOH in patients with a clinically important active infection until the infection resolves or is adequately treated. If a serious infection develops, do not administer OMVOH until the infection resolves. (5.2)
- Tuberculosis: Do not administer OMVOH to patients with active TB infection. Monitor patients receiving OMVOH for signs and symptoms of active TB during and after treatment. (5.3)
- Hepatotoxicity: Drug-induced liver injury has been reported. Monitor liver enzymes and bilirubin levels at baseline and for at

least 24 weeks of treatment and thereafter according to routine patient management. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. (5.4)

Immunizations: Avoid use of live vaccines. (5.5)

ADVERSE REACTIONS

Most common adverse reactions (≥2%) are:

- Induction: upper respiratory tract infections and arthralgia. (6.1)
- Maintenance: upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection. (6.1)

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Evaluations and Immunizations Prior to
- Treatment Initiation
- 2.2 Recommended Dosage
- 2.3 Preparation and Administration of OMVOH for Intravenous
- 2.4 Preparation and Administration of OMVOH for
- Subcutaneous Injection
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Hypersensitivity Reactions
- 5.2 Infections 5.3 Tuberculosis
- 5.4 Hepatotoxicity
- 5.5 Immunizations

6 ADVERSE REACTIONS 6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics 12.3 Pharmacokinetics
- 12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
- * Sections or subsections omitted from the full prescribing information are not listed.